Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Roman, E; Cooney, E; Harrison, L; Militano, O; Wolownik, K; Hawks, R; Foley, S; Satwani, P; Unal, ELİF; Bhatia, M; Bradley, B; Del Toro, G; George, D; Garvin, J; van deVen, C; Cairo, MS

doi:10.1158/1078-0432.ccr-1004-0018

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Roman E., Cooney E., Harrison L., Militano O., Wolownik K., Hawks R., ...Daha Fazla

Clinical cancer research : an official journal of the American Association for Cancer Research, cilt.11, sa.19 Pt 2, 2005 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 11 Sayı: 19 Pt 2
Basım Tarihi: 2005
Doi Numarası: 10.1158/1078-0432.ccr-1004-0018
Dergi Adı: Clinical cancer research : an official journal of the American Association for Cancer Research
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Ankara Üniversitesi Adresli: Hayır

Özet

Purpose: Myeloablative allogeneic stem cell transplantation (SCT) has been successful in the treatment of childhood acute myeloid leukemia (AML), but may be associated with significant toxicity and recurrent disease. Reduced-intensity allogeneic SCT may offer a less toxic approach to patients with AML. Targeted immunotherapy with gemtuzumab ozogamicin has been shown to be safe, well tolerated in children, and, as a single agent, gemtuzumab ozogamicin has induced responses in 30% of patients with recurrent CD33(+) AML. There are no safety data with gemtuzumab ozogamicin post allogeneic SCT in children. Therefore, we explored the feasibility and toxicity of targeted immunotherapy following reduced-intensity allogeneic SCT in children with CD33(+) AML.